A physiologically ‐based pharmacokinetic/pharmacodynamic modeling approach for drug–drug‐gene interaction evaluation of S‐warfarin with fluconazole
This study provides a whole-body physiologically-based pharmacokinetic/PD (PBPK/PD) model of S-warfarin for predicting the effects of drug–drug−gene interactions on S-warfarin PKs and PDs. The PBPK/PD model of S-warfarin was developed in PK-Sim and MoBi. Drug-depende nt parameters were obtained from the literature or optimized. Of the 34 S-warfarin plasma concentration-time profiles used, 96% predicted plasma concentrations within twofold range compared to observed data. For S-warfarin plasma concentration-time profiles withCYP2C9 genotype, 364 of 386 predicted plasma concentration values (~94%) fell within the twofold...
Source: CPT: Pharmacometrics and Systems Pharmacology - March 15, 2024 Category: Drugs & Pharmacology Authors: Kuo Geng,
Chaozhuang Shen,
Xiaohu Wang,
Xingwen Wang,
Wenxin Shao,
Wenhui Wang,
Tao Chen,
Hua Sun,
Haitang Xie Tags: ARTICLE Source Type: research
Risk of intracranial hemorrhage in patients using anticoagulant therapy for atrial fibrillation after cerebral microbleeds combined with acute ischemic stroke: a meta-analysis
ConclusionAnticoagulant therapy for ischemic stroke patients with non-valvular AF and CMBs increases future ICH risk. Discontinuing anticoagulation due to ICH risk should be avoided. NOACs are safe and effective for patients with CMBs and IS. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - March 15, 2024 Category: Neurology Source Type: research
Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists
In patients undergoing revascularization for peripheral arterial disease (PAD), low-dose Factor Xa inhibitors (FXaI) taken with aspirin improved limb and cardiovascular outcomes compared to aspirin alone. Further, in atrial fibrillation and venous thromboembolism, FXaI are recommended over vitamin K antagonists (VKA) for chronic anticoagulation. While studies have evaluated different perioperative anticoagulation regimens in patients treated for PAD, the optimal regimen for chronic anticoagulation in patients with PAD undergoing PVI has not been determined. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - March 15, 2024 Category: Surgery Authors: Joshua J. Huttler, Dana Alameddine, Fachreza Aryo Damara, Paula Pinto- Rodriguez, Zhen Wu, Martin Slade, David Strosberg, Cassius Iyad Ochoa Chaar Tags: Clinical Research Source Type: research
Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease
CONCLUSION: In a retrospective study on patients with advanced chronic kidney disease and atrial fibrillation, OAC was associated with overall decreased 1-year risk of thromboembolic event and death offset by increased 1-year risk of major bleeding.PMID:38481950 | PMC:PMC10933578 | DOI:10.1016/j.rpth.2024.102350 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 14, 2024 Category: Hematology Authors: Ellen Linnea Freese Ballegaard Jonas Bjerring Olesen Anne-Lise Kamper Bo Feldt-Rasmussen Gunnar Gislason Christian Torp-Pedersen Nicholas Carlson Source Type: research
Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease
CONCLUSION: In a retrospective study on patients with advanced chronic kidney disease and atrial fibrillation, OAC was associated with overall decreased 1-year risk of thromboembolic event and death offset by increased 1-year risk of major bleeding.PMID:38481950 | PMC:PMC10933578 | DOI:10.1016/j.rpth.2024.102350 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 14, 2024 Category: Hematology Authors: Ellen Linnea Freese Ballegaard Jonas Bjerring Olesen Anne-Lise Kamper Bo Feldt-Rasmussen Gunnar Gislason Christian Torp-Pedersen Nicholas Carlson Source Type: research
Deficiency of protein C or protein S as a possible cause of osteoporosis
AbstractProteins C and S are vitamin K-dependent anticoagulative factors that also exert a significant influence on bone quality. Clinical studies have linked the deficiency of proteins C and S to lower bone mineral density and the onset of femoral head osteonecrosis in children. Rare foundational studies analyzing this topic have demonstrated that activated protein C, upon binding to the endothelial protein C receptor expressed on the surface of osteoblasts, promotes osteoblast proliferation. It is also established that proteins C and S play crucial roles in proper collagen synthesis and in maintaining the number of osteo...
Source: Endocrine - March 14, 2024 Category: Endocrinology Source Type: research
Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa
This study assessed the quality of anticoagulation and associated factors among VKA-treated patients in nine SSA countries. We conducted a retrospective cohort study of randomly selected patients on anticoagulation from 20 clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania, and South Africa. Eligible participants were those on VKAs for at least three months and with at least four international normalised ratios (INR) results in 2019 –2021. We report the proportion of INR values in the therapeutic range, time-in-therapeutic range (TTR) using the Rosendaal method, ...
Source: Journal of Thrombosis and Thrombolysis - March 13, 2024 Category: Hematology Source Type: research
Direct Oral Anticoagulants for Pulmonary Embolism
Hamostaseologie. 2024 Mar 11. doi: 10.1055/a-2105-8736. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism ...
Source: Hamostaseologie - March 11, 2024 Category: Hematology Authors: Roberto Pizzi Ludovica Anna Cimini Walter Ageno Cecilia Becattini Source Type: research
Direct Oral Anticoagulants for Pulmonary Embolism
Hamostaseologie. 2024 Mar 11. doi: 10.1055/a-2105-8736. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism ...
Source: Hamostaseologie - March 11, 2024 Category: Hematology Authors: Roberto Pizzi Ludovica Anna Cimini Walter Ageno Cecilia Becattini Source Type: research
Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study — In Reply
In Reply We appreciate the insights provided by Khan et al and Tzeng and Tsai regarding our study. As noted in the study limitations, although the use of prescription data from the claims database is superior to self-reported medication use, this method may not fully capture patient nonadherence, which could be a potential risk for misclassification. The best pragmatic approach to verify the time elapsed since the most recent dose of non −vitamin K antagonist oral anticoagulants (NOACs) is to use medication adherence monitoring devices (eg, ingestible electronic sensor) or noninvasive medication compliance monitoring sys...
Source: JAMA Internal Medicine - March 11, 2024 Category: Internal Medicine Source Type: research
Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study
To the Editor We read with interest the nationwide population-based cohort study with meta-analysis by Tsai et al. The study findings showed that patients who received non-vitamin K antagonist oral anticoagulants (NOACs) before a stroke, compared with those receiving warfarin and those without oral anticoagulant treatment (non-OAC), did not experience a higher risk of intracranial hemorrhage (ICH), major bleeding events, or mortality when treated with intravenous alteplase for acute ischemic stroke. In comparison with the active comparator (warfarin group), the odds ratios (ORs) were 0.88 (95% CI, 0.32-2.40) for ICH, 0.82 ...
Source: JAMA Internal Medicine - March 11, 2024 Category: Internal Medicine Source Type: research
